

## **Inimex Co-Founder Bob Hancock Receives 2006 Michael Smith Prize**

**FOR IMMEDIATE RELEASE**

**Vancouver, B.C., Canada – November 27, 2006.**

Inimex Pharmaceuticals, Inc. is pleased to announce that Inimex scientific co-founder Dr. R.E. (Bob) Hancock has been awarded the Michael Smith Prize as Canadian Health Researcher of the Year by the Canadian Institute of Health Research (CIHR) for his research on ways of battling infectious diseases in hospitals and nursing homes.

A Professor of Microbiology & Immunology at the University of British Columbia and Canada Research Chair in Pathogenomics & Antimicrobials, Dr. Hancock is also a Fellow of the Royal Society of Canada, the American Academy of Microbiology, and the Infectious Disease Society of America.

The Michael Smith Prize recognizes innovation, creativity, leadership and dedication to health research. The award is one of many acknowledgments of Dr. Hancock's prolific and distinguished scientific career. He is the author of more than 400 scientific publications and 21 patents, and has served as an advisor to multiple biotechnology and pharmaceutical companies. He has also been awarded the Canadian Society of Microbiologists Award, the McLaughlin Medal of the Royal Society of Canada and the Aventis Pharmaceuticals Award from the American Society of Microbiology.

"This award is well deserved. Bob is truly a world leader in characterizing and exploiting the role of host peptides in innate immunity" noted Inimex CEO John North. "His remarkable understanding of this emerging field has enabled him to pioneer new biological insights and continuously innovate novel antimicrobial products. Based on Bob's research and ongoing guidance, Inimex is developing novel first in class Innate Defense Regulator (IDR) products for the prevention and treatment of disease in high risk individuals. IDR products show great promise for addressing antibiotic resistance and pathological inflammation, major issues for patients who are immune compromised due to hospitalization, advanced age, or drug therapy."

Hancock received his award from Canada's Minister of Health, The Honorable Tony Clement, in Ottawa November 22.

### About Inimex Pharmaceuticals, Inc.

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of Innate Defense Regulator products, novel first in class drugs that selectively trigger the body's innate defenses without causing inflammation. Innate Defense Regulator products have major market potential for infectious disease, cancer, and inflammatory disease.

For further information, please visit the company website, [www.inimexpharma.com](http://www.inimexpharma.com) or contact:

Roger Graham, Ph.D.  
Vice President, Corporate Development  
Inimex Pharmaceuticals, Inc.  
Tel: 604-225-2251  
Fax: 604-225-2257  
[rgraham@inimexpharma.com](mailto:rgraham@inimexpharma.com)